Compare
MoonLake Immunotherapeutics vs Arcutis Biotherapeutics, Inc. vs Harrow, Inc. vs Xeris Biopharma Holdings, Inc.
| Latest fiscal year | MoonLake Immunotherapeutics MLTX | Arcutis Biotherapeutics, Inc. ARQT | Harrow, Inc. HROW | Xeris Biopharma Holdings, Inc. XERS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $372.07M | $272.30M | $291.85M |
| Revenue growth (YoY) | n/a | +123.4% | +36.4% | +43.7% |
| Gross margin | n/a | 90.1% (computed) | 75.1% | n/a |
| Operating margin | n/a | -3.3% | 11.2% | 8.5% |
| Net margin | n/a | -4.3% | -1.9% | 0.2% |
| Net income | -$227.32M | -$16.14M | -$5.14M | $554.0K |
| EPS (Diluted) | -$3.53 | -$0.13 | -$0.14 | $0.00 |
| Operating cash flow | -$196.01M | -$5.62M | $43.86M | $28.63M |
| Free cash flow | -$196.04M | -$6.31M | $42.98M | n/a |
| Cash & equivalents | $334.52M | $42.91M | $72.93M | $111.04M |
| Total assets | $424.43M | $432.97M | $399.48M | $383.53M |
| Total liabilities | $119.95M | $243.49M | $347.39M | $369.84M |
| Shareholders' equity | $304.48M | $189.48M | $52.45M | $13.69M |
| Return on year-end equity | -74.7% | -8.5% | -9.8% | 4.0% |
| Shares outstanding | n/a | 123.33M | 37.23M | 166.22M |
Revenue, most recent five fiscal years
| Fiscal year | MoonLake Immunotherapeutics | Arcutis Biotherapeutics, Inc. | Harrow, Inc. | Xeris Biopharma Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | $372.07M Ended 2025-12-31 | $272.30M Ended 2025-12-31 | $291.85M Ended 2025-12-31 |
| 1 year earlier | n/a | $166.54M Ended 2024-12-31 | $199.61M Ended 2024-12-31 | $203.07M Ended 2024-12-31 |
| 2 years earlier | n/a | $59.61M Ended 2023-12-31 | $130.19M Ended 2023-12-31 | $163.91M Ended 2023-12-31 |
| 3 years earlier | n/a | $3.69M Ended 2022-12-31 | $88.59M Ended 2022-12-31 | $110.25M Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | $72.48M Ended 2021-12-31 | $49.59M Ended 2021-12-31 |